Anti-factor B antibodies in atypical hemolytic uremic syndrome
Authors:
- 22 January 2024
- journal article
- research article
- Published by Springer Nature in Pediatric Nephrology
- Vol. 39 (6) , 1909-1916
Abstract
Background The etiology of atypical hemolytic uremic syndrome (aHUS) is unknown in 30–40% of patients. Anti-factor B (FB) antibodies are reported in C3 glomerulopathy (C3G) and immune-complex membranoproliferative glomerulonephritis (IC-MPGN), though not in aHUS. Methods We screened patients < 18-year-old from cohorts of aHUS and C3G/idiopathic IC-MPGN. Anti-FB IgG antibodies were measured by ELISA and confirmed by Western blot. Normative levels were based on antibody levels in 103 healthy blood donors. Results Prevalence of anti-FB antibodies was 9.7% (95% CI 6.1–14.5%; n = 21) in 216 patients with aHUS, including 11.5% (95% CI 6.4–18.5%; n = 14) in anti-FH associated aHUS and 11.8% (95% CI 4.4–23.9%; n = 6) in patients without a definitive genetic or autoimmune etiology. Patients with significant genetic variants did not show anti-FB antibodies. In patients with concomitant anti-FB and anti-FH antibodies, median anti-FH titers were higher (11,312 AU/mL vs. 4920 AU/mL; P = 0.04). Anti-FB antibody titer correlated with disease severity (hemoglobin and platelets; P < 0.05), declined following plasma exchange and increased during relapse. While 4/64 patients with C3G (6.3%) and 1/17 with IC-MPGN showed anti-FB antibodies, titers were higher in aHUS (544.8 AU/mL vs. 1028.8 AU/mL; P = 0.003). Conclusion Anti-FB antibodies are present in 6–10% of patients with aHUS and C3G/IC-MPGN, with higher titers in the former. The diagnostic and therapeutic implication of anti-FB antibodies in aHUS needs confirmation and further studies. The study shows propensity for autoantibody generation and co-existence of multiple risk factors for aHUS in Indian children. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary informationKeywords
All Related Versions
Funding Information
- Indian Council of Medical Research (5/7/1090/2013-RHN, 5/4/7-18/Nephro/2020-NCDII)
- Department of Biotechnology, Government of India (BT/PR11030/MED/30/1644/2016)
This publication has 39 references indexed in Scilit:
- Complement Factor H–Related Protein 1 Deficiency and Factor H Antibodies in Pediatric Patients with Atypical Hemolytic Uremic SyndromeClinical Journal of the American Society of Nephrology, 2013
- Factor I Autoantibodies in Patients with Atypical Hemolytic Uremic SyndromeClinical Journal of the American Society of Nephrology, 2012
- NoticeKidney International Supplements, 2012
- Combined C3b and Factor B Autoantibodies and MPGN Type IINew England Journal of Medicine, 2011
- Clinical Features of Anti-Factor H Autoantibody–Associated Hemolytic Uremic SyndromeJournal of the American Society of Nephrology, 2010
- Anti-factor B autoantibody in dense deposit diseaseMolecular Immunology, 2010
- New Equations to Estimate GFR in Children with CKDJournal of the American Society of Nephrology, 2009
- Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiencyBlood, 2008
- Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndromeProceedings of the National Academy of Sciences, 2007
- Approved recommendation (1986) on the theory of reference values. Part 1. The concept of reference values.Clinica Chimica Acta, 1987